Holen Sie sich die Stockscreener-App
3.84
4.95%
-0.20
Handel nachbörslich:
3.84
Schlusskurs vom Vortag:
$4.04
Offen:
$4.01
24-Stunden-Volumen:
1.37M
Relative Volume:
0.96
Marktkapitalisierung:
$409.32M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-134.24M
KGV:
-2.1695
EPS:
-1.77
Netto-Cashflow:
$-121.34M
1W Leistung:
-7.02%
1M Leistung:
-25.15%
6M Leistung:
-40.09%
1J Leistung:
-7.58%
1-Tages-Spanne:
$3.81
$4.045
1-Wochen-Bereich:
$3.81
$4.2796
52-Wochen-Spanne:
$3.81
$8.40
Annexon Inc Stock (ANNX) Company Profile
Firmenname
Annexon Inc
Sektor
Branche
Telefon
(650)-822-5500
Adresse
1400 SIERRA POINT PARKWAY, BRISBANE
Vergleichen Sie ANNX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
3.84 | 409.32M | 0 | -134.24M | -121.34M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-10-30 | Eingeleitet | Wells Fargo | Overweight |
| 2023-05-26 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-05-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-09-16 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | BTIG Research | Buy |
| 2021-11-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-09-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-01-26 | Eingeleitet | Needham | Buy |
| 2020-08-18 | Eingeleitet | BofA Securities | Buy |
| 2020-08-18 | Eingeleitet | Cowen | Outperform |
| 2020-08-18 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Annexon Inc Aktie (ANNX) Neueste Nachrichten
What's Driving These Stocks Higher In After-hours? - RTTNews
Vanguard Group Inc's Strategic Acquisition of Annexon Inc Shares - GuruFocus.com
Annexon, Inc. (NASDAQ:ANNX) Short Interest Update - MarketBeat
Annexon stock touches 52-week low at $3.85 amid market challenges - Investing.com Nigeria
Critical Survey: Day One Biopharmaceuticals (NASDAQ:DAWN) vs. Annexon (NASDAQ:ANNX) - Defense World
Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals - MSN
Cantor Fitzgerald Estimates Annexon FY2025 Earnings - Defense World
Annexon, Inc. (NASDAQ:ANNX) Given Average Rating of “Buy” by Brokerages - Defense World
Annexon, Inc. (NASDAQ:ANNX) Given Average Rating of "Buy" by Brokerages - MarketBeat
Guillain-Barré Syndrome Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Chafic Karam, Hansa Biopharma AB, Annexon - The Globe and Mail
Guillain-Barre Syndrome Market to Reach New Heights in Growth - openPR
Annexon (NASDAQ: ANNX) Issues Press Release Outlining 2025 Outlook - Defense World
Hennion & Walsh Asset Management Inc. Boosts Position in Annexon, Inc. (NASDAQ:ANNX) - MarketBeat
Barclays PLC Boosts Stake in Annexon, Inc. (NASDAQ:ANNX) - MarketBeat
Barclays PLC Acquires 120,789 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year - GlobeNewswire
Annexon Advances Three Breakthrough Therapies, Including First Targeted GBS Treatment - StockTitan
JPMorgan Chase & Co. Has $10.10 Million Stake in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon Expands Board with Appointment of New Member William Jones - Defense World
Annexon Biosciences Strengthens Board for Strategic Growth - TipRanks
Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones - GlobeNewswire
Annexon Strengthens Board with Commercial Veteran BJ Jones Ahead of Late-Stage Drug Launches - StockTitan
ANNXAnnexon, Inc. Latest Stock News & Market Updates - StockTitan
Jane Street Group LLC Sells 39,601 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon: Breakthrough In Guillain-Barré Faces Upcoming FDA Hurdles (NASDAQ:ANNX) - Seeking Alpha
Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Annexon (NASDAQ:ANNX) Stock Price Down 4.3%Here's Why - MarketBeat
Franklin Resources Inc. Acquires Shares of 49,406 Annexon, Inc. (NASDAQ:ANNX) - Defense World
Barclays PLC Has $1.05 Million Holdings in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Geode Capital Management LLC Grows Stake in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by Geode Capital Management LLC - MarketBeat
Annexon, Inc. (NASDAQ:ANNX) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Annexon, Inc. (NASDAQ:ANNX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by State Street Corp - Defense World
Annexon (ANNX) Surges with Promising Phase 3 Results for Guillain-Barré Syndrome Treatment - TipRanks
State Street Corp Has $22.74 Million Stake in Annexon, Inc. (NASDAQ:ANNX) - MarketBeat
Annexon (NASDAQ:ANNX) Shares Down 3.8%Time to Sell? - MarketBeat
HC Wainwright Reaffirms Buy Rating for Annexon (NASDAQ:ANNX) - Defense World
New Data Supports BLA Package - Streetwise Reports
Annexon (NASDAQ:ANNX) Given Buy Rating at HC Wainwright - MarketBeat
Annexon shares rise on positive Guillain-Barré study results By Investing.com - Investing.com Australia
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Annexon Awards Major Stock Options Package to New Hires in Strategic Talent Acquisition Move - StockTitan
Annexon shares rise on positive Guillain-Barré study results - Investing.com
Annexon (NASDAQ:ANNX) Shares Gap UpWhat's Next? - MarketBeat
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS) - The Manila Times
Finanzdaten der Annexon Inc-Aktie (ANNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):